US Prioritizes American AI Integration in Asia Following TrumpXi Meeting CNBC Portfolio Manager Takes Profits on Stock That Rose 46 in One Week 80 Since April Standard Chartered Targets Higher Returns with Over 15 Job Cuts in Corporate Functions Aims for 20 Income Per Employee Boost by 2028 Inflation Expected to Reach 6 in Q2 According to Top Economic Forecasters Crossroads Capitals Thesis on Nebius Group NBIS Shows Promise Amid Market Turmoil Post Office Horizon Scandal Inquiry Faces FiveYear Delay Without Extra Funding Police Warn COOK Q1 2026 Earnings Surprise Profit Beat Sends Mixed Signals as Revenue Details Remain Unclear PEBK Q4 2025 Earnings Strong EPS Performance Amid Quiet Trading Applied Industrial Technologies AIT Q1 2026 Earnings Slight EPS Miss Amid Steady Demand Volato Group Inc SOAR Q2 2025 Earnings Positive EPS Reported Amid Market Caution WEAV Q1 2026 Earnings EPS Surprise of 2931 Drives Positive Market Reaction Kazia Therapeutics Q1 2026 Earnings A WiderThanExpected Loss Yet Shares Gain Ground Pliant Therapeutics PLRX Holds Near Support Amid Modest Gains Key Levels in Focus IREN Limited IREN Dips 212 as Crypto Mining Stocks Face Broad Pressure Pentair PNR Holds Steady as Support and Resistance Levels Define Trading Range Brinks Company BCO Holds Steady Near 105 Amid Tight Trading Range Sutro Biopharma STRO Consolidates Near Resistance Biotech Stock Shows Modest Gains OpenAI Prepares to File for IPO as AI Sector Awaits Landmark Public Listing HAE Q1 2026 Earnings EPS Slightly Beats Estimates Shares Edge Higher YPF Stock Gains 127 as Support Holds Near 4617 Amphastar Pharmaceuticals AMPH Q1 2026 Earnings EPS Misses Estimates by Over 40 Yet Stock Rises AGM Q1 2026 Earnings EPS Surpasses Estimates Stock Edges Higher ANIP Q1 2026 Earnings Strong EPS Beat Driven by Operational Execution UFPI Q1 2026 Earnings EPS Falls Short as Cost Pressures Mount AVB Q1 2026 Earnings Strong Core FFO Beat Driven by Solid Rent Growth and High Occupancy Indaptus Therapeutics Q4 2025 Earnings EPS Miss Amid Continued RD Investment TNGX Q1 2026 Earnings EPS Misses Consensus as PreRevenue Biotech Advances Pipeline